scholarly journals HER2 Receptor Overexpression in Gastric Adenocarcinoma A Study about a Sampling of 50 Cases in Dakar

2019 ◽  
Vol 4 (3) ◽  
pp. 1-6
Author(s):  
Bentefouet TL
Keyword(s):  
Gastric Adenocarcinoma ◽  
Poor Prognosis ◽  
Gastroesophageal Junction ◽  
Immunohistochemical Method ◽  
Clinicopathological Parameters ◽  
Her2 Status ◽  
Her2 Overexpression ◽  
Her2 Receptor ◽  
Male Predominance ◽  
One Year

ntroduction: HER2 receptor overexpression in gastric or gastroesophageal junction (GOJ) adenocarcinoma is a factor of poor prognosis detected in 7 to 34% of gastric and GOJ adenocarcinomas. The objective of this study was to evaluate the overexpression of the HER2 receptor in gastric adenocarcinomas in Dakar, and to investigate the correlation between HER2 overexpression and clinicopathological parameters. Patients and method: This is a retrospective, descriptive and analytical study that was conducted over a one - year period; from 1 January 2016 to 31 December 2017. It involves 50 cases of gastric or GOJ adenocarcinomas histologically confirmed on biopsy samplings, collected within pathological anatomy and cytology services in Dakar (HALD a nd HOGGY). The study of HER2 receptor overexpression was performed on tumor samples put in buffered formalin and embedded in paraffin using the immunohistochemical method. Results: The average age was 58.18 ± 14.6 years. A male predominance was observed, w ith a gender ratio of 1.27. Tumors were ulcero budding in 76% of cases. They were found at the gastric level in 92% of the surveyed cases, and at the gastroesophageal junction in 8% of them. Adenocarcinomas were of tubulous type in 76% of cases, and they w ere markedly differentiated in 54% of cases. At immunohistochemical study, the positivity rate of the HER2 was 8% out of the 50 cases that were tested. There was no correlation between HER2 overexpression and those clinicopathological parameters . Con clusion: HER2 is a factor of poor prognosis but it is also a therapeutic response factor to anti - HER2s. Assessment of the HER2 status should be systematic in all cases of gastric adenocarcinoma; and it requires a multidisciplinary approach.

Two updates on adenocarcinoma of gastroesophageal junction from the fifth WHO classification of tumors of the digestive system: alteration of gastroesophageal junction definition and the emphasis on HER2 test.

2020 ◽  
Author(s):  
Yunzhu Li ◽  
Jiayu Li ◽  
Manji Li
Keyword(s):  
Gastric Adenocarcinoma ◽  
Who Classification ◽  
Gastroesophageal Junction ◽  
Clinicopathological Features ◽  
Gastric Body ◽  
Clinicopathological Parameters ◽  
Her2 Expression ◽  
Fourth Edition ◽  
Gastric Tumors

Abstract Background: The incidence of gastroesophageal junction (GEJ) adenocarcinoma has increased rapidly but remains controversial over the last decades. There are two crucial updates of the fifth WHO classification including the alteration of GEJ location and the emphasize on human epidermal growth factor receptor 2 (HER2) test.Methods: We retrospectively analyzed the clinicopathological features of 566 patients suffered from gastric adenocarcinoma. We comprehensively compared the clinicopathological features among GEJ and non-GEJ tumors, GEJ and proximal and distal gastric tumors with fourth and fifth edition, respectively. Besides, we discussed the correlation of the HER2 expression with clinicopathological features according to the fifth WHO classification.Results: The results showed that the difference was mainly between GEJ and distal adenocarcinoma in the fourth edition, but some were between proximal and distal adenocarcinoma in the fifth edition. Tumors with longer invasion of the oesophagus were still mainly concentrated in GEJ tumors. The expression of HER2 in GEJ and proximal gastric adenocarcinoma was still higher than that in gastric body and distal site, which was basically consistent with the conclusion of the fourth edition classification.Conclusions: The clinicopathological parameters of the GEJ tumors partly changed with the narrowing scope of the GEJ adenocarcinoma. The proximal gastric tumors rather than GEJ tumors tended to be more invasive. But the GEJ tumors with longer oesophageal invasion required additional management. The HER2-expression of GEJ adenocarcinoma is still higher than that of other gastric sites. The classification of the fifth edition is reasonable and worthy of recommendation.

scholarly journals Relative Prognostic Value of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Operable Oesophagogastric Cancer

ISRN Surgery ◽  
2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
David S. Y. Chan ◽  
Fiona Campbell ◽  
Paul Edwards ◽  
Bharat Jasani ◽  
Geraint T. Williams ◽  
...  
Keyword(s):  
Prognostic Significance ◽  
Growth Factor Receptor ◽  
High Specificity ◽  
Endoscopic Biopsy ◽  
Receptor Expression ◽  
Her2 Status ◽  
Her2 Overexpression ◽  
Her2 Receptor ◽  
Her2 Positive ◽  
Predictive Values

Aims. The aim of this study was to determine the prognostic significance of HER2 receptor expression in operable oesophagogastric adenocarcinoma. Methods. Eighty-five consecutive patients diagnosed with oesophagogastric adenocarcinoma [18 oesophageal (OC), 32 junctional (JC) and 35 gastric (GC)] undergoing potentially curative resection were studied retrospectively. Immunohistochemistry was used to determine HER2 status at endoscopic biopsy and resection specimen. The primary outcome measure was survival. Results. Twenty (24%) patients had HER2 positive tumours which was commoner in JC (14/32, 44% versus 2/18, 11% in OC and 4/35, 11% in GC, P=0.003). The sensitivity, specificity, positive and negative predictive values of HER2 status at endoscopic biopsy were 56%, 93%, 63%, 91% respectively (weighted Kappa=0.504, P<0.0001). Five-year survival in OC HER2 positive negative was 100% and 36% (P=0.167) compared with 14% and 44% (P=0.0726) in JC and 50% and 46% (P=0.942) in GC respectively. Conclusions. Endoscopic biopsy had a high specificity and negative predictive value in determining HER2 status. Patients with JC had a significantly higher rate of HER2 overexpression and this was associated with a nonsignificant poorer survival trend. A larger study is needed to confirm these findings because of the implications for neoadjuvant and adjuvant chemotherapy regimens.

Impact of Specimen Type and Specimen Number on HER2 Status in Gastroesophageal Junction and Gastric Adenocarcinoma

2019 ◽  
Vol 151 (5) ◽  
pp. 461-468 ◽  
Author(s):  
Aaron R Huber ◽  
Brandon Buscaglia ◽  
Brooke R Koltz ◽  
Jill Henry ◽  
Loralee McMahon ◽  
...  
Keyword(s):  
Gastric Adenocarcinoma ◽  
Gastroesophageal Junction ◽  
Her2 Status ◽  
Specimen Type ◽  
Specimen Number

HER2-overexpression/amplification and survival in patients with resectable esophageal/gastroesophageal junction adenocarcinoma (E/GEJ-AC) treated with neoadjuvant carboplatin/paclitaxel-based chemoradiation.

2021 ◽  
Vol 39 (3_suppl) ◽  
pp. 239-239
Author(s):  
Yening Feng ◽  
Cristobal Tomas Sanhueza Condell ◽  
Christopher Leigh Hallemeier ◽  
Shanda H Blackmon ◽  
Joleen M. Hubbard ◽  
...  
Keyword(s):  
Gastroesophageal Junction ◽  
Pathologic Complete Response ◽  
Disease Free Survival ◽  
Her2 Status ◽  
Similar Proportion ◽  
Her2 Overexpression ◽  
Lower Grade ◽  
Prognostic Impact ◽  
Her2 Positive ◽  
Her2 Positivity

239 Background: After trastuzumab (T) approval for advanced HER2-positive E/GEJ-AC, HER2 testing has increased in patients (pts) with resectable disease. Neoadjuvant carboplatin/paclitaxel chemoradiation (nCP-CRT) is a common therapy approach. We performed the largest evaluation, to our knowledge, of the prognostic impact of HER2 in E/GEJ-AC pts treated with nCP-CRT. Methods: We retrospectively reviewed medical records of all trimodality-eligible (T2+ or N+) pts with E/GEJ-AC who started nCP-CRT (usually 50.4 Gy) with planned surgery at Mayo Clinic (2014-2019). HER2 was tested using standard criteria for HER2 positivity (ie, immunohistochemistry 3+ or amplification by in situ hybridization). Clinicopathologic data and time to recurrence (TTR), disease free survival (DFS), overall survival (OS), survival after recurrence (SAR), and pathologic complete response (pCR – ie, no residual tumor in primary or nodes) were collected. Kaplan Meier and multivariate Cox analysis were used. Results: Of 161 consecutive eligible pts, HER2 status was available in 107 pts (HER2-positive n=26, HER2-negative n=81) of whom n=82 had surgery and n=19 had pCR. Most tumors were clinical T3 (80%) or N+ (81%), histologic grade 3 of 3 (62%). HER2 positivity was significantly associated with lower grade, but not with age, clinical T or N, or ECOG performance status (PS). A similar proportion of HER2-positive ( vs negative) pts had surgery. Among pts who had surgery, pCR rates were lower in HER2-positive ( vs negative) pts (11% [2/19] vs 27% [17/63]). After a median follow up of 23 mo, DFS and TTR were significantly shorter in HER2 positive ( vs negative) pts, independent of other pretreatment covariables (Table). Yet OS was comparable. Lung recurrence was enriched in HER2 positive ( vs negative) pts. Among pts with recurrence, SAR was longer in HER2-positive vs -negative pts. A total of 53% (10/19) of previously HER2-positive pts received T-based therapy after recurrence, and these pts were the drivers of favorable SAR (median 22 mo in n=10 HER2-positive pts who received T vs 11 mo in n=9 HER2-positive pts who did not receive T vs 11 mo in n=40 HER2-negative pts; P log-rank=.01). Conclusions: HER2 positivity ( vs negativity) is independently associated with shorter TTR and DFS, but more comparable OS. The adverse association of HER2 on tumor response and TTR may have been largely overcome through enhanced survival after recurrence, although OS data are maturing. These data may have implications for the design of endpoints in future curative-intent anti-HER2 trials. [Table: see text]

Evaluation of serum HER2 extracellular domain in in metastatic gastric or gastroesophageal junction cancer: Correlation with HER2 status by immunohistochemistry and fluorescence in situ hybridization and clinicopathologic parameters.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 4107-4107
Author(s):  
Xin An ◽  
Shuqin Dai ◽  
Fang Wang ◽  
Qiong Shao ◽  
Cui Chen ◽  
...  
Keyword(s):  
In Situ Hybridization ◽  
Gastroesophageal Junction ◽  
Locally Advanced ◽  
Surrogate Marker ◽  
High Specificity ◽  
Extracellular Domain ◽  
High Serum ◽  
Clinicopathological Parameters ◽  
Her2 Status

4107 Background: To explore the association between serum human epidermal growth factor receptor-2 (HER2) extracellular domain (ECD) and tissue HER2 status, their relationship with clinicopathological parameters and impact on overall survival (OS) in metastatic gastric or gastro-oesophageal junction (GEJ) adenocarcinoma. Methods: A total of 219 histologically confirmed inoperable locally advanced, recurrent, or metastatic gastric or GEJ adenocarcinoma were included. Serum HER2 ECD was measured by chemiluminescent assay. Tissue HER2 status was accessed by fluorescent in situ hybridization (FISH) and immunohistochemistry (IHC) assay. Results: The median serum ECD level was 9.3 ng/ml (range 3.0 to >350). Tissue HER2 status was positive (IHC3+ or 2+ with FISH amplification) in 37 patients (16.9%) and negative in 182 patients (83.1%). Statistically significant associations were found between serum HER2 ECD level and HER2 status assessed by IHC and FISH. The ROC-analysis suggested the cutoff of 16.35 ng/ml (24 of 219 patients had HER2 ECD >16.35 ng/ml ) could produce a sensitivity of 51.4% and a specificity of 97.3% to predict tissue HER2 status. If the cutoff value was increaseed to 22 ng/ml, then all 12 patients with serum HER2 ECD >22 ng/ml were HER 2 positive in primary tumor, corresponding to a specificity of 100% and a sensitivity of 32.4%. High serum HER2 ECD levels were strongly associated with liver metastasis (P < 0.001), the intestinal histologic type (Lauren's classification) (P =0.003), large number of metastais (>2) (P=0.012) and increased LDH level (P < 0.001) . High serum HER2 ECD levels were more common in GEJ adenocarcinoma although the difference had no stastical significance. HER2 ECD levels did not show a significant impact on OS. Conclusions: A significant association was observed between serum HER2 ECD levels and tissue HER2 status in metastasis gastric or GEJ adenocarcinoma. The high specificity of serum HER2 ECD assay to predict tissue HER2 status suggests its potential use as a surrogate marker of the HER2 status in gastric cancer.

scholarly journals Study of HER-2/neu status in adenocarcinoma of stomach and gastroesophageal junction

2020 ◽  
Vol 8 (12) ◽  
pp. 4388
Author(s):  
Nigar Fathima ◽  
Michelle De Padua ◽  
Swarnalata Gowrishankar ◽  
Iravathy Goud
Keyword(s):  
Gastroesophageal Junction ◽  
Growth Factor Receptor ◽  
Tumor Grade ◽  
Intestinal Type ◽  
Clinicopathological Parameters ◽  
Her2 Status ◽  
Fish Analysis ◽  
Chi Square ◽  
Her 2 ◽  
Epidermal Growth

Background: To study the expression of Human epidermal growth factor receptor 2 (HER-2/neu) in adenocarcinoma of stomach and gastroesophageal junction and to study and describe the association of HER-2/neu expression with various clinicopathological parameters in Indian population.Methods: Immunohistochemical testing was done on 91 cases diagnosed as adenocarcinoma of gastric and gastroesophageal junction by histological examination to determine HER2 status. HER2 amplification was confirmed by fluorescence in situ hybridization (FISH) on cases that had equivocal (immunohistochemistry-IHC score 2+) HER2 expression. The association between HER-2 positivity and clinicopathological parameters was assessed by Chi-square test.Results: The HER-2 IHC results are as follows: score 3+ (positive): 8.79%; score 2+ (equivocal): 10.99%; score 0 and 1+ (negative): 80.22%. Of the 10 cases of equivocal IHC results, 2 cases (20%) showed amplification of HER-2 gene demonstrated by dual probe FISH analysis. The overall prevalence of HER-2 positivity detected using immunohistochemistry and FISH was 10.99% (10/91 cases). HER-2 positivity correlated with the tumor grade (well and moderately differentiated tumor, p=0.013) and intestinal type (p=0.025) but not with age, gender, pathological stage and lymph node metastasis.Conclusions: HER-2 positivity in our study was 10.99%. HER-2 positivity significantly correlated with intestinal type of adenocarcinoma and the grade of the tumor. Two cases with strong HER-2 staining but in less than 10% of the tumor showed gene amplification by FISH.

HER2 OVEREXPRESSION IN ENDOSCOPIC BIOPSY SAMPLE OF GASTRIC ADENOCARCINOMA BY IMMUNOHISTOCHEMISTRY

2012 ◽  
pp. 109-118
Author(s):  
Viet Nho Le ◽  
Van Huy Tran ◽  
Cong Thuan Dang ◽  
Van To Ta
Keyword(s):  
Gastric Adenocarcinoma ◽  
Undifferentiated Carcinoma ◽  
Signet Ring Cell Carcinoma ◽  
Signet Ring Cell ◽  
Endoscopic Biopsy ◽  
Her2 Overexpression ◽  
Tubular Adenocarcinoma ◽  
Signet Ring ◽  
Poorly Differentiated ◽  
Well Differentiated

Background and aim: HER2 overexpression by immunohistochemistry is a prognostic maker in gastric cancer and helps to select candidates benefitted from targeted therapy with trastuzumab. This study is aimed at the assessing HER2 overexpression and its relationship with endoscopic and histopathological findings of gastric adenocarcinoma. Objectives and methods: Biopsy samples from 92 gastric cancer patients were examined for HER2 status by immunohistochemical staining. Results: 6.5% of tumors were cardia tumors and 93.5% were non-cardia tumors. Using the Lauren classification, 51.1% were intestinal type and 48.9% were diffuse type. Using WHO classification, 54.3% were tubular adenocarcinoma, 7.6% were mucinous adenocarcinoma, 15.2% were signet-ring cell carcinoma, and 22.8% were undifferentiated carcinoma. 32.6% were well-differentiated, 15.2% were moderately-differentiated, and 52.2% were poorly-differentiated carcinoma. HER2 was positive in 20.7% of gastric carcinomas, 50% cardia tumors and 18.6% non-cardia tumors. HER2 positivity among polypoid, fungating, ulcerated, and infiltrative types were 38.5%, 29.7%, 9.1% and 0%, respectively. HER2 overexpression in intestinal type was higher than that in diffuse type (31.9% vs. 8.9%, p = 0.009). HER2 overexpression in tubular adenocarcinoma, mucinous adenocarcinoma, signet-ring cell carcinoma, and undifferentiated carcinoma was 28.0%, 14.3%, 7.1% and 14.3%, respectively. HER2 overexpressions were different between differentiation degrees: 30% of well-differentiated tumors, 35.7% moderately-differentiated tumors, and 10.4% of poorly-differentiated tumors (p = 0.037). Conclusions: HER2 overexpression was found in 20.7% of endoscopic biopsy sample of gastric adenocarcinoma and was associated with endoscopic gross characteristic, Lauren histologic type and differentiation degree.

Sign in / Sign up

Export Citation Format

Share Document